Overview

Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy

Status:
NOT_YET_RECRUITING

Trial end date:
2028-03-01

Target enrollment:

Participant gender:

Summary

A phase 3, prospective, adaptive, randomized, multicenter, double-blind, triple-masked, parallel clinical trial to evaluate the efficacy and safety of N0750 in relieving pain associated with painful diabetic peripheral neuropathy (PDPN).

Phase:

PHASE3

Details

Lead Sponsor:

Eurofarma Laboratorios S.A.

Treatments:

Duloxetine Hydrochloride
Pregabalin